Free Trial

Stratos Wealth Partners LTD. Sells 12,580 Shares of CVS Health Corporation (NYSE:CVS)

CVS Health logo with Medical background

Stratos Wealth Partners LTD. lowered its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 31.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,077 shares of the pharmacy operator's stock after selling 12,580 shares during the period. Stratos Wealth Partners LTD.'s holdings in CVS Health were worth $1,834,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hopwood Financial Services Inc. bought a new stake in shares of CVS Health in the 4th quarter valued at about $29,000. McIlrath & Eck LLC grew its position in shares of CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 174 shares during the last quarter. Park Square Financial Group LLC bought a new stake in shares of CVS Health in the 4th quarter valued at about $43,000. PARK CIRCLE Co grew its position in shares of CVS Health by 42.9% in the 4th quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock valued at $45,000 after buying an additional 300 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL grew its position in shares of CVS Health by 77.2% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 1,024 shares of the pharmacy operator's stock valued at $46,000 after buying an additional 446 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Analysts Set New Price Targets

CVS has been the topic of a number of analyst reports. Royal Bank Of Canada upped their price target on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. UBS Group upped their target price on CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a research report on Friday, May 2nd. Robert W. Baird upped their target price on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research report on Tuesday, April 15th. Mizuho upped their target price on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Finally, Morgan Stanley restated an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.06.

Read Our Latest Report on CVS

CVS Health Stock Performance

Shares of CVS Health stock opened at $65.58 on Friday. The company has a market cap of $82.96 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51. The business has a 50 day moving average price of $65.10 and a 200-day moving average price of $62.08. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.31 earnings per share. Equities analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.06%. The ex-dividend date is Tuesday, July 22nd. CVS Health's dividend payout ratio (DPR) is presently 63.48%.

Insider Activity

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the completion of the acquisition, the director directly owned 12,007 shares in the company, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.22% of the stock is currently owned by corporate insiders.

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Read More

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines